Vivo Bio Tech Ltd. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 650679, "name": "Vivo Bio Tech", "stock_name": "Vivo Bio Tech", "full_name": "Vivo Bio Tech Ltd.", "name_url": "stocks-analysis/vivo-bio-tech", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "22.73", "chg": 0.15, "chgp": "0.66%", "dir": 1, "prev_price": "22.58", "mcapval": "51.00 Cr", "mcap": "Micro Cap", "scripcode": 511509, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE380K01017", "curr_date": "Jun 24, 12:37 PM", "curr_time": "12:42 PM", "last_traded_at": "Jun 24, 12:37 PM IST", "bse_nse_vol": "2.87 k", "exc_status": "Active", "traded_date": "Jun 24, 2026", "traded_date_str": "2026 06 24", "score": "", "scoreText": "", "Live": 1, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vivo-bio-tech-650679-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Vivo Bio Tech Ltd. is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/vivo-bio-tech-ltd-is-rated-strong-sell-4061028", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/VivoBioTechLtd_mojoScore_4061028.png", "date": "2026-06-18 10:11:09", "description": "Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 June 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Vivo Bio Tech Ltd. Falls 11.28%: Key Financial and Technical Challenges Weigh on Stock", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivo-bio-tech-ltd-falls-1128-key-financial-and-technical-challenges-weigh-on-stock-4052352", "imagepath": "", "date": "2026-06-13 17:19:55", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>1 June:</strong> Q4 FY26 results reveal ₹5.16 crore loss despite revenue growth</p>\n <p><strong>2 June:</strong> Sharp decline in quarterly financial performance amid market pressure</p>\n <p><strong>2 June:</strong> Downgrade to Strong Sell rating by MarketsMOJO</p>\n <p><strong>5 June:</strong> Week closes at Rs.24.45, down 11.28%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.27.56</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-valu..." }, { "title": "Are Vivo Bio Tech Ltd. latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-vivo-bio-tech-ltd-latest-results-good-or-bad-4032361", "imagepath": "", "date": "2026-06-02 19:26:50", "description": "Vivo Bio Tech Ltd. reported its financial results for the quarter ending March 2026, revealing a complex operational landscape. The company achieved a net sales figure of ₹14.20 crores, marking a 5.11% quarter-on-quarter increase and a 15.54% year-on-year growth, indicating a strong demand for its preclinical research services. This revenue growth represents the seventh consecutive quarter of sequential increases, suggesting an upward trend in client engagement and utilization of its research facilities.\n\nHowever, the company's net profit reflected a significant loss of ₹5.16 crores, a stark contrast to the profit of ₹1.25 crores reported in the previous quarter. This drastic decline in profitability was primarily attributed to an exceptional tax charge that resulted in an extraordinarily high effective tax rate of 2,164%. This one-time adjustment overshadowed the positive revenue growth and raised concerns..." }, { "title": "Vivo Bio Tech Ltd. Reports Sharp Decline in Quarterly Financial Performance Amid Market Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivo-bio-tech-ltd-reports-sharp-decline-in-quarterly-financial-performance-amid-market-pressure-4030809", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/VivoBioTechLtd_fintrenddot_4030809.png", "date": "2026-06-02 11:00:14", "description": "Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its financial performance for the quarter ended March 2026. Despite achieving its highest quarterly net sales to date, the company’s profitability and operational efficiency have sharply declined, prompting a downgrade to a Strong Sell rating by MarketsMOJO as of 1 June 2026." }, { "title": "Vivo Bio Tech Ltd. Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals", "link": "https://www.marketsmojo.com/news/stock-recommendation/vivo-bio-tech-ltd-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-4030090", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/VivoBioTechLtd_mojoScore_4030090.png", "date": "2026-06-02 08:31:01", "description": "Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 1 June 2026. This adjustment reflects deteriorating fundamentals, worsening technical indicators, and a bleak financial trend, signalling heightened risk for investors amid sustained underperformance against benchmarks." }, { "title": "Vivo Bio Tech Q4 FY26: Exceptional Tax Charge Triggers ₹5.16 Crore Loss Despite Revenue Growth", "link": "https://www.marketsmojo.com/news/result-analysis/vivo-bio-tech-q4-fy26-exceptional-tax-charge-triggers-516-crore-loss-despite-revenue-growth-4028730", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/VivoBioTech_quaterlyResult_4028730.png", "date": "2026-06-01 14:41:11", "description": "Vivo Bio Tech Ltd., a contract research organisation specialising in drug development and discovery services, reported a shocking net loss of ₹5.16 crores in Q4 FY26, a dramatic reversal from the ₹1.25 crore profit in the previous quarter. The loss, driven by an extraordinary tax charge of ₹5.41 crores representing a staggering 2,164.00% effective tax rate, overshadowed an otherwise improving operational performance with revenue reaching a quarterly high of ₹14.20 crores. The stock plunged 10.67% to ₹24.62 following the results announcement, reflecting investor concern over the deteriorating profitability despite sequential revenue growth of 5.11%." }, { "title": "Vivo Bio Tech Ltd. Upgraded to Sell on Technical Improvements Despite Weak Fundamentals", "link": "https://www.marketsmojo.com/news/stock-recommendation/vivo-bio-tech-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-4015915", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivoBioTechLtd_mojoScore_4015915.png", "date": "2026-05-27 08:08:33", "description": "Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 26 May 2026. This change is primarily driven by a shift in technical indicators, despite ongoing challenges in financial performance and valuation metrics. The company’s stock price currently trades at ₹27.18, down 1.84% on the day, reflecting mixed signals from market participants." }, { "title": "When is the next results date for Vivo Bio Tech Ltd.?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-vivo-bio-tech-ltd-4015098", "imagepath": "", "date": "2026-05-26 23:18:30", "description": "The next results date for Vivo Bio Tech Ltd. is scheduled for 29 May 2026...." }, { "title": "Vivo Bio Tech Ltd. Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals", "link": "https://www.marketsmojo.com/news/stock-recommendation/vivo-bio-tech-ltd-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-4004472", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivoBioTechLtd_mojoScore_4004472.png", "date": "2026-05-22 08:09:02", "description": "Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 21 May 2026. This revision reflects deteriorating technical indicators, stagnant financial performance, and subdued valuation metrics, signalling heightened risks for investors amid a challenging market environment." } ], "total": 111, "sid": "650679", "stock_news_url": "https://www.marketsmojo.com/news/vivo-bio-tech-650679" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "13-Jun-2026", "details": "Newspaper advertisement - Notice of postal ballot & e-voting", "source": "BSE" }, { "caption": "Shareholder Meeting / Postal Ballot-Notice of Postal Ballot", "datetime": "12-Jun-2026", "details": "Please find enclosed Postal Ballot Notice", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "09-Jun-2026", "details": "Newspaper publication of notice for special window for re-lodgement of transfer request of physical shares", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

1 June: Q4 FY26 results reveal ₹5.16 crore loss despite revenue growth

2 June: Sharp decline in quarterly financial performance amid market pressure

2 June: Downgrade to Strong Sell rating by MarketsMOJO

5 June: Week closes at Rs.24.45, down 11.28%

Week Open

Rs.27.56

Week Close

Read full news article

Are Vivo Bio Tech Ltd. latest results good or bad?

2026-06-02 19:26:50

Vivo Bio Tech Ltd. reported its financial results for the quarter ending March 2026, revealing a complex operational landscape. The company achieved a net sales figure of ₹14.20 crores, marking a 5.11% quarter-on-quarter increase and a 15.54% year-on-year growth, indicating a strong demand for its preclinical research services. This revenue growth represents the seventh consecutive quarter of sequential increases, suggesting an upward trend in client engagement and utilization of its research facilities. However, the company's net profit reflected a significant loss of ₹5.16 crores, a stark contrast to the profit of ₹1.25 crores reported in the previous quarter. This drastic decline in profitability was primarily attributed to an exceptional tax charge that resulted in an extraordinarily high effective tax rate of 2,164%. This one-time adjustment overshadowed the positive revenue growth and raised concerns...

Read full news article

Vivo Bio Tech Ltd. Reports Sharp Decline in Quarterly Financial Performance Amid Market Pressure

2026-06-02 11:00:14

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its financial performance for the quarter ended March 2026. Despite achieving its highest quarterly net sales to date, the company’s profitability and operational efficiency have sharply declined, prompting a downgrade to a Strong Sell rating by MarketsMOJO as of 1 June 2026.

Read full news article

Vivo Bio Tech Ltd. Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

2026-06-02 08:31:01

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 1 June 2026. This adjustment reflects deteriorating fundamentals, worsening technical indicators, and a bleak financial trend, signalling heightened risk for investors amid sustained underperformance against benchmarks.

Read full news article

Vivo Bio Tech Q4 FY26: Exceptional Tax Charge Triggers ₹5.16 Crore Loss Despite Revenue Growth

2026-06-01 14:41:11

Vivo Bio Tech Ltd., a contract research organisation specialising in drug development and discovery services, reported a shocking net loss of ₹5.16 crores in Q4 FY26, a dramatic reversal from the ₹1.25 crore profit in the previous quarter. The loss, driven by an extraordinary tax charge of ₹5.41 crores representing a staggering 2,164.00% effective tax rate, overshadowed an otherwise improving operational performance with revenue reaching a quarterly high of ₹14.20 crores. The stock plunged 10.67% to ₹24.62 following the results announcement, reflecting investor concern over the deteriorating profitability despite sequential revenue growth of 5.11%.

Read full news article

Vivo Bio Tech Ltd. Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

2026-05-27 08:08:33

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 26 May 2026. This change is primarily driven by a shift in technical indicators, despite ongoing challenges in financial performance and valuation metrics. The company’s stock price currently trades at ₹27.18, down 1.84% on the day, reflecting mixed signals from market participants.

Read full news article

When is the next results date for Vivo Bio Tech Ltd.?

2026-05-26 23:18:30

The next results date for Vivo Bio Tech Ltd. is scheduled for 29 May 2026....

Read full news article

Vivo Bio Tech Ltd. Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-05-22 08:09:02

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 21 May 2026. This revision reflects deteriorating technical indicators, stagnant financial performance, and subdued valuation metrics, signalling heightened risks for investors amid a challenging market environment.

Read full news article